FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386438739> ?p ?o ?g. }

• W4386438739 endingPage "11" @default.
• W4386438739 startingPage "1" @default.
• W4386438739 abstract "<b><i>Introduction:</i></b> Patients with cancer may be at a higher risk of experiencing severe complications from coronavirus disease 2019 (COVID-19) than are patients without cancer. This study evaluated the efficacy of REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, for treating COVID-19 in patients with cancer in the USA. <b><i>Methods:</i></b> Using the MarketScan^Ⓡ database, de-identified data of patients with a COVID-19 diagnosis between November 1, 2020, and November 30, 2021, were analyzed. In the preliminary study, patients with COVID-19 were divided into two groups: those with and without cancer within 1 year prior to a COVID-19 diagnosis. In the main study, patients with COVID-19 with cancer were divided into two groups: those with and without REGEN-COV treatment. Patient outcomes, such as COVID-19-derived hospitalization, hospitalization duration, and medical costs, were assessed between these two groups by propensity score matching. <b><i>Results:</i></b> Within the first 30 days of a COVID-19 diagnosis, the group treated with REGEN-COV had fewer hospitalizations (3.2% vs. 13.3%; <i>p</i> &lt; 0.001), fewer mean hospitalization days (0.2 vs. 1.1 days; <i>p</i> &lt; 0.001), and a lower mean-associated medical payment (2,709 vs. 8,120 USD; <i>p</i> &lt; 0.001) than the group not treated with REGEN-COV. Patients with specific cancer types, including non-Hodgkin’s lymphoma, leukemia, and lung cancer, had higher hospitalization rates than those with other cancer types. <b><i>Conclusion:</i></b> Patients with cancer treated with REGEN-COV experienced a decreased risk for hospitalization, hospitalization duration, and total COVID-19-related costs. Patients with cancer were at a higher risk of being hospitalized for COVID-19 than were those without cancer. The use of neutralizing antibody therapy may reduce the risk of severe COVID-19 infection for patients with cancer with an otherwise high risk. Future replication studies should be conducted using other databases that include Medicaid users and other insured persons for comparison and validation." @default.
• W4386438739 created "2023-09-06" @default.
• W4386438739 creator A5072656639 @default.
• W4386438739 date "2023-09-04" @default.
• W4386438739 modified "2023-10-12" @default.
• W4386438739 title "Retrospective Case-Control Study of REGEN-COV (Casirivimab and Imdevimab) Therapy for Patients with COVID-19 and Cancer Using the United States MarketScan^® Database" @default.
• W4386438739 cites W1519785298 @default.
• W4386438739 cites W2121656227 @default.
• W4386438739 cites W2132761689 @default.
• W4386438739 cites W2808880546 @default.
• W4386438739 cites W3004318991 @default.
• W4386438739 cites W3008394341 @default.
• W4386438739 cites W3042427819 @default.
• W4386438739 cites W3046463683 @default.
• W4386438739 cites W3080162924 @default.
• W4386438739 cites W3092131843 @default.
• W4386438739 cites W3112675846 @default.
• W4386438739 cites W3116049377 @default.
• W4386438739 cites W3167210620 @default.
• W4386438739 cites W3174054271 @default.
• W4386438739 cites W4200443953 @default.
• W4386438739 cites W4205090031 @default.
• W4386438739 cites W4206451540 @default.
• W4386438739 cites W4213457834 @default.
• W4386438739 doi "https://doi.org/10.1159/000533614" @default.
• W4386438739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37666220" @default.
• W4386438739 hasPublicationYear "2023" @default.
• W4386438739 type Work @default.
• W4386438739 citedByCount "0" @default.
• W4386438739 crossrefType "journal-article" @default.
• W4386438739 hasAuthorship W4386438739A5072656639 @default.
• W4386438739 hasConcept C121608353 @default.
• W4386438739 hasConcept C126322002 @default.
• W4386438739 hasConcept C167135981 @default.
• W4386438739 hasConcept C17923572 @default.
• W4386438739 hasConcept C2779134260 @default.
• W4386438739 hasConcept C3007834351 @default.
• W4386438739 hasConcept C3008058167 @default.
• W4386438739 hasConcept C524204448 @default.
• W4386438739 hasConcept C71924100 @default.
• W4386438739 hasConcept C90924648 @default.
• W4386438739 hasConceptScore W4386438739C121608353 @default.
• W4386438739 hasConceptScore W4386438739C126322002 @default.
• W4386438739 hasConceptScore W4386438739C167135981 @default.
• W4386438739 hasConceptScore W4386438739C17923572 @default.
• W4386438739 hasConceptScore W4386438739C2779134260 @default.
• W4386438739 hasConceptScore W4386438739C3007834351 @default.
• W4386438739 hasConceptScore W4386438739C3008058167 @default.
• W4386438739 hasConceptScore W4386438739C524204448 @default.
• W4386438739 hasConceptScore W4386438739C71924100 @default.
• W4386438739 hasConceptScore W4386438739C90924648 @default.
• W4386438739 hasLocation W43864387391 @default.
• W4386438739 hasLocation W43864387392 @default.
• W4386438739 hasOpenAccess W4386438739 @default.
• W4386438739 hasPrimaryLocation W43864387391 @default.
• W4386438739 hasRelatedWork W3084498529 @default.
• W4386438739 hasRelatedWork W3176864053 @default.
• W4386438739 hasRelatedWork W3198183218 @default.
• W4386438739 hasRelatedWork W4205317059 @default.
• W4386438739 hasRelatedWork W4205810683 @default.
• W4386438739 hasRelatedWork W4206548596 @default.
• W4386438739 hasRelatedWork W4206651655 @default.
• W4386438739 hasRelatedWork W4206669628 @default.
• W4386438739 hasRelatedWork W4224279380 @default.
• W4386438739 hasRelatedWork W4292098121 @default.
• W4386438739 isParatext "false" @default.
• W4386438739 isRetracted "false" @default.
• W4386438739 workType "article" @default.